Filing Details

Accession Number:
0001209191-21-051885
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-17 16:44:45
Reporting Period:
2021-08-13
Accepted Time:
2021-08-17 16:44:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1678660 Prelude Therapeutics Inc PRLD Pharmaceutical Preparations (2834) 811384762
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1824632 Peggy Scherle C/O Prelude Therapeutics Incorporated
200 Powder Mill Road
Wilmington DE 19803
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-13 558 $1.89 173,478 No 4 M Direct
Common Stock Acquisiton 2021-08-13 1,728 $1.43 175,206 No 4 M Direct
Common Stock Disposition 2021-08-13 2,286 $35.07 172,920 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-08-13 558 $0.00 558 $1.89
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-08-13 1,728 $0.00 1,728 $1.43
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
42,672 2030-03-26 No 4 M Direct
34,732 2028-11-12 No 4 M Direct
Footnotes
  1. Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
  2. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  4. The stock option vested as to 25% of the total shares monthly beginning on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
  5. The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.